Calidi Biotherapeutics Inc (AMEX:CLDI) has a beta value of 1.05 and has seen 1.0 million shares traded in the last trading session. The company, currently valued at $32.63M, closed the last trade at $1.75 per share which meant it lost -$0.1 on the day or -5.41% during that session. The CLDI stock price is -1254.29% off its 52-week high price of $23.70 and 58.29% above the 52-week low of $0.73. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.03 million shares traded. The 3-month trading volume is 1.47 million shares.
Calidi Biotherapeutics Inc (AMEX:CLDI) trade information
Sporting -5.41% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the CLDI stock price touched $1.75 or saw a rise of 13.37%. Year-to-date, Calidi Biotherapeutics Inc shares have moved -88.41%, while the 5-day performance has seen it change -9.33%. Over the past 30 days, the shares of Calidi Biotherapeutics Inc (AMEX:CLDI) have changed -12.94%. Short interest in the company has seen 0.59 million shares shorted with days to cover at 0.88.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Wall Street analysts have a consensus price target for the stock at $5.5, which means that the shares’ value could jump 68.18% from current levels. The projected low price target is $2.0 while the price target rests at a high of $9.0. In that case, then, we find that the current price level is -414.29% off the targeted high while a plunge would see the stock gain -14.29% from current levels.
Calidi Biotherapeutics Inc (CLDI) estimates and forecasts
Figures show that Calidi Biotherapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -10.26% over the past 6 months, with this year growth rate of 74.10%, compared to 16.90% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
CLDI Dividends
Calidi Biotherapeutics Inc is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Calidi Biotherapeutics Inc (AMEX:CLDI)’s Major holders
Insiders own 18.16% of the company shares, while shares held by institutions stand at 2.71% with a share float percentage of 3.31%. Investors are also buoyed by the number of investors in a company, with Calidi Biotherapeutics Inc having a total of 34.0 institutions that hold shares in the company.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Extended Market Index Fund and Bridgeway Funds Inc-Ultra Small Company Market Fund . As of Oct 31, 2024 , the former fund manager holds about 0.15% shares in the company for having 31.17 shares of worth $54540.0 while later fund manager owns 10.0 shares of worth $17500.0 as of Sep 30, 2024 , which makes it owner of about 0.05% of company’s outstanding stock.
